Is BPC-157 the same as TB-500?

No. BPC-157 is a synthetic 15-amino-acid peptide. TB-500 is a synthetic 7-amino-acid fragment related to thymosin beta-4. They are different molecules with different literature.

Can you stack BPC-157 and TB-500?

This site does not recommend stacking unapproved research chemicals. There is no robust human evidence base for either as an approved therapy, and combination protocols online are not substitutes for clinical research.

Which is better for healing?

Neither has the kind of human clinical package that would let a careful reader declare a winner for injury healing. BPC-157 has a large rodent literature; TB-500 is frequently confused with full-length thymosin beta-4.

Research peptidesbpc-157 vs tb-500

BPC-157 vs TB-500: How the Two Differ

Two different molecules with different literatures, sold as one healing stack. Structure, human data, legal status and WADA bans, side by side.

Written bySebastian Hunter, Founder and Editor

Published July 16, 2026Updated August 22, 2026

Start here

Plain English

BPC-157 and TB-500 are different molecules with different research behind them, though marketing often blurs them into a single healing stack. Neither has an approved human therapy package, so compare structure, evidence and legal status separately.

They are not the same peptide and do not share one evidence base.
Stacking guides online are not clinical evidence.
Both sit outside approved medicine in the US consumer research-chemical market.

Vendors sell BPC-157 vs TB-500 like two brands of the same idea. Chemically and evidentially, they are not.

Side by side

	BPC-157	TB-500
What the name means	BPC = body protection compound; 157 is a serial designation. A researcher label, not a demonstrated effect	TB is generally read as thymosin beta. The name points at a protein this is only a fragment of - see the trap below
What it is	Synthetic 15-aa peptide (gastric-derived sequence lineage)	Synthetic 7-aa fragment (Ac-LKKTETQ), not full Tβ4
Human efficacy	Reviews: efficacy not confirmed in humans; not approved	No published human RCT of the fragment we could locate
Common trap	Over-reading rodent work	Citing full-length thymosin beta-4 as if it were TB-500
WADA 2026	S0 Non-Approved Substances	S2.3 Tβ4 and derivatives e.g. TB-500
US approval	Not FDA-approved	Not FDA-approved

Full pages: BPC-157 · TB-500

BPC-157 in one paragraph

BPC-157 has a large rodent literature. A 2019 review states efficacy is yet to be confirmed in humans. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. (opens PubMed in a new tab) A 2025 review states it has not been approved due to insufficient comprehensive clinical studies. Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2). (opens PubMed in a new tab) Mechanistic and animal work continues to be published; that is not the same as a finished human evidence package. Hsieh 2017 - Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. (opens PubMed in a new tab)

TB-500 in one paragraph

TB-500 is not thymosin beta-4. It is a short acetylated fragment. Much of the “proof” people paste under TB-500 is literature on the 43-aa protein - the wrong molecule for the vial on the table.

Evidence meters (honest)

BPC-157

Limited human data

Small or uncontrolled human studies. Too little to settle the question either way. Extensive preclinical work; human clinical package insufficient for approval per recent review language; one historical human RCT context exists in the wider literature but is not a modern efficacy program.

TB-500

Animal / lab only

Studied in cells or animals. No controlled trials in humans. Fragment frequently confused with full-length Tβ4; no published human RCT of the heptapeptide for tissue-repair indications located.

Stacking

Online “BPC + TB stacks” are marketing protocols, not controlled clinical programmes. This site does not endorse stacking unapproved research chemicals.

References

Bibliographic detail is fetched from PubMed, not written by us - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than our judgement.

1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
3.Hsieh MJ, Liu HT, Wang CN et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333.StudyPMID 27847966
4.WADA 2026 Prohibited List - BPC-157 under S0; Thymosin-ß4 and derivatives e.g. TB-500 under S2.3 (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory
5.Wikipedia - TB-500. Secondary source for Ac-LKKTETQ structure and fragment-versus-parent distinction.- Wikipediaother